Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
journal contributionposted on 17.02.2021, 05:17 by Hui Gan
• Optimal use of phase II data may reduce chances of failure in subsequent phase III studies.
• Inappropriate utilization or a lack of phase II data appears to contribute to phase III failure.
• Only 35% of phase III trials in our review transitioned from phase II to III in an optimal manner.